China National Pharmaceutical Group Co Ltd (Sinopharm), a flagship player in the pharmaceutical industry and a key contributor to building a global community of health for all, demonstrated a strong commitment to the sixth China International Import Expo (CIIE), which opened in Shanghai on Nov 5. 

For the sixth consecutive session, the company invited foreign participants to exhibit and organized delegations to engage in procurement and exhibition activities. 

Sinopharm’s trade delegation at the event was led by Deputy General Manager and Spokesman Jin Bin, with over 50 enterprises at various levels represented by more than 500 attendees. 

The signing ceremony of Sinopharm’s agreements with its partners took place on Nov 7. This year, the company continued to expand collaborations with foreign partners, signing 21 procurement agreements with leading medical equipment and dietary supplement companies from the United States, Germany, Canada, Japan, Sweden, the Netherlands and other nations. The number of signed agreements increased by 30 percent to a record high. 

Notably, breakthroughs were made in the contract volume in key areas such as high-end medical equipment manufacturing, medical devices and imported dietary supplements, contributing to a continuous rise in the total amount of contracts. This achievement not only maintained stability but also achieved an upward trend, once again breaking historical records. 

Sinopharm consistently stood out in import agreements in the pharmaceutical and medical equipment sectors, showcasing the domestic pharmaceutical industry's development opportunities and leading the way towards a more open, inclusive, beneficial, balanced and win-win development.

Participants pose for a commemorative photo at the signing ceremony of Sinopharm’s deals with its partners at the sixth CIIE. [Photo/sinopharm.com] 

In the current global context of insufficient economic recovery momentum and escalating geopolitical conflicts, the remarkable achievements made by the Sinopharm delegation at this year’s CIIE carry extraordinary significance. They reflect the company's steadfast dedication to the Healthy China 2030 initiative and signify its determination and confidence in deepening strategic cooperation with globally leading pharmaceutical and healthcare enterprises to safeguard public health.

Representatives attend the signing ceremony of Sinopharm’s deals with its partners at the sixth CIIE. [Photo/sinopharm.com] 

Sinopharm, through in-depth cooperation with partner enterprises, provided innovative and internationally leading localized solutions to serve the Chinese market. Together, they focused on the life science sector and contributed to high-quality innovation and development in the industry. 

Guided by the corporate philosophy of “All for Health, Health for All”, the company has fulfilled its responsibilities as a central State-owned enterprise, enabling more people to enjoy better health services. 

The sixth CIIE attracted delegates from 154 countries and regions as well as international organizations to this global gathering. 

With 72 countries and international organizations participating in the Country Exhibition and over 3,400 enterprises from 128 countries and regions joining professional exhibitions, this year’s event marked the largest number of Fortune Global 500 companies, industry leaders, and innovative small and medium-sized enterprises in its history.